Volume 32, Issue 152 (May & June 2024)                   J Adv Med Biomed Res 2024, 32(152): 219-225 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mirzaei B. Evaluation of Antibiotic Sensitivity, Biofilm Formation Ability, and Prevalence of Extended-Spectrum Beta-Lactamase (ESBLs) in Clinically Isolates Escherichia coli and Klebsiella pneumoniae. J Adv Med Biomed Res 2024; 32 (152) :219-225
URL: http://journal.zums.ac.ir/article-1-7414-en.html
Department of Medical Microbiology and Virology, School of Medicine, Zanjan University of Medical Science, Zanjan, Iran , dr.bahman.m@gmail.com
Abstract:   (636 Views)
Background & Objective: Extended-spectrum beta-lactamases (ESBLs) are enzymes in bacteria that resist many antibiotics. Detection of ESBLs production is important as it's a marker of colonization and potential transfer to other patients. We studied the antibiotic susceptibility, biofilm formation capacity, and prevalence of ESBLs of opportunistic bacteria including K. pneumoniae and E. coli. The isolates capable of biofilm formation were analyzed among 100 E. coli and 104 K. pneumoniae isolates.
 Materials & Methods: This process involved collecting and identifying bacterial samples, testing antibiotic susceptibility, detecting ESBLs phenotypes, and multidrug-resistance (MDR) isolates, assessing biofilm formation capability, and evaluating results through statistical analysis.
 
Results: The susceptibility tests for discs were performed following the guidelines outlined by the Clinical Laboratory Standards Institute in 2023 (CLSI). K. pneumoniae exhibits inherent resistance to ampicillin, while 80 (80%) strains of E. coli have been reported to be resistant to ampicillin. Additionally, 50 K. pneumoniae isolates and 41 E. coli isolates were found capable of forming a biofilm. Seven of E. coli (17.07%), and seven of K. pneumoniae (14%) isolates could form a mighty biofilm. It was observed that the strongest resistance in the isolates that formed strong biofilm was related to tetracycline with 5 (7.2%) resistance in K. pneumonia and 7 (7%) resistance in E. coli. Furthermore, 47 (47%) of E. coli, and 21 (20.2%) of K. pneumoniae isolates were classified as ESBLs producers, and 52 (50%) K. pneumoniae and 72 (72%) E. coli isolates were classified as MDR.

Conclusion: Considering the role of biofilm in the transfer of genes, appropriate health policies, and the correct administration of effective antibiotics can help in prevention.
 
Full-Text [PDF 562 kb]   (201 Downloads)    
Type of Study: Original Research Article | Subject: Life Science
Received: 2023/12/26 | Accepted: 2024/08/19 | Published: 2024/06/21

References
1. Vila J, Sáez-López E, Johnson JR, Römling U, Dobrindt U, Cantón R, et al. Escherichia coli: an old friend with new tidings. FEMS Microbiol Rev. 2016; 40(4): 437-63. [DOI:10.1093/femsre/fuw005]
2. Pitout JDD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015; 59(10): 5873-84. [DOI:10.1128/AAC.01019-15]
3. Kaper JB, Nataro JP, Mobley HL. Pathogenic escherichia coli. Nature Rev Microbiol. 2004; 2(2): 123-40. [DOI:10.1038/nrmicro818]
4. Aye SM, Galani I, Yu H, Wang J, Chen K, Wickremasinghe H, et al. Polymyxin triple combinations against polymyxin-resistant, multidrug-resistant, KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020; 64(8): e00246-20. [DOI:10.1128/AAC.00246-20]
5. Vuotto C, Longo F, Balice MP, Donelli G, Varaldo PE. Antibiotic resistance related to biofilm formation in Klebsiella pneumoniae. Pathogens. 2014; 3(3): 743-58. [DOI:10.3390/pathogens3030743]
6. Matuschek E, Åhman J, Webster C, Kahlmeter G. Antimicrobial susceptibility testing of colistin-evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. Clin Microbiol Infect. 2018; 24(8): 865-70. [DOI:10.1016/j.cmi.2017.11.020]
7. Parte A, Whitman WB, Goodfellow M, Kämpfer P, Busse H-J, Trujillo ME, et al. Bergey's manual of systematic bacteriology: volume 5: the Actinobacteria: Springer Science & Business Media; 2012.
8. Osman EA, El-Amin N, Adrees EA, Al-Hassan L, Mukhtar M. Comparing conventional, biochemical and genotypic methods for accurate identification of Klebsiella pneumoniae in Sudan. Access Microbiol. 2020; 2(3). [DOI:10.1099/acmi.0.000096]
9. He Y, Guo X, Xiang S, Li J, Li X, Xiang H, et al. Comparative analyses of phenotypic methods and 16S rRNA, khe, rpoB genes sequencing for identification of clinical isolates of Klebsiella pneumoniae. Antonie Van Leeuwenhoek. 2016; 109(7): 1029-40. [DOI:10.1007/s10482-016-0702-9]
10. Dasen G, Smutny J, Teuber M, Meile L. Classification and identification of propionibacteria based on ribosomal RNA genes and PCR. System Apply Microbiol. 1998; 21(2): 251-9. [DOI:10.1016/S0723-2020(98)80030-1]
11. https://clsi.org/media/pjfbviql/m100ed34e_sample.pdf. CLSI M100.
12. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas M, Giske C, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18(3): 268-81. [DOI:10.1111/j.1469-0691.2011.03570.x]
13. Drieux L, Brossier F, Sougakoff W, Jarlier V. Phenotypic detection of extended‐spectrum β‐lactamase production in Enterobacteriaceae: review and bench guide. Clin Microbiol Infect. 2008; 14: 90-103. [DOI:10.1111/j.1469-0691.2007.01846.x]
14. Yousefi Mashouf R, Alijani P, Saidijam M, Alikhani MY, Rashidi H. Study of antibiotic resistance pattern and phenotypic detection of ESBLs in Klebsiella pneumoniae strains isolated from clinical samples and determination of minimum inhibitory concentrations of imipenem and ceftazidim antibiotics. Avicenna J Clin Med. 2014; 20(4): 295-302.
15. Burton E, Yakandawala N, LoVetri K, Madhyastha M. A microplate spectrofluorometric assay for bacterial biofilms. J Indust Microbiol Biotechnol. 2007; 34(1): 1-4. [DOI:10.1007/s10295-006-0086-3]
16. Stepanović S, Vuković D, Dakić I, Savić B, Švabić-Vlahović M. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Method. 2000; 40(2): 175-9. [DOI:10.1016/S0167-7012(00)00122-6]
17. Mostafavi SN, Rostami S, Nejad YR, Ataei B, Mobasherizadeh S, Cheraghi A, et al. Antimicrobial resistance in hospitalized patients with community acquired urinary tract infection in Isfahan, Iran. Arch Iran Med. 2021; 24(3): 187-92. [DOI:10.34172/aim.2021.29]
18. Tanhaei S, Mahmoudi S, Pournajafi A, Mahmoudi A. Investigating the antibiotic resistance pattern of extended spectrum beta lactamase producing Klebsiella pneumoniae isolates from urinary tract infections in Zanjan city, Iran. Int J Biol Genetic. 2020.
19. Vaez H, Sahebkar A, Khademi F. Carbapenem-Resistant Klebsiella pneumoniae in Iran: a systematic review and meta-analysis. J Chemother. 2019; 31(1): 1-8. [DOI:10.1080/1120009X.2018.1533266]
20. Lopes E, Saavedra MJ, Costa E, de Lencastre H, Poirel L, Aires-de-Sousa M. Epidemiology of carbapenemase-producing Klebsiella pneumoniae in northern Portugal: Predominance of KPC-2 and OXA-48. J Glob Antimicrob Resist. 2020; 22: 349-53. [DOI:10.1016/j.jgar.2020.04.007]
21. Shadkam S, Goli HR, Mirzaei B, Gholami M, Ahanjan M. Correlation between antimicrobial resistance and biofilm formation capability among Klebsiella pneumoniae strains isolated from hospitalized patients in Iran. Ann Clin Microbiol Antimicrob. 2021; 20: 1-7. [DOI:10.1186/s12941-021-00418-x]
22. Mirzaei B, Babaei R, Bazgir ZN, Goli HR, Keshavarzi S, Amiri E. Prevalence of Enterobacteriaceae spp. and its multidrug-resistant rates in clinical isolates: a two-center cross-sectional study. Molec Biol Report. 2021; 48: 665-75. [DOI:10.1007/s11033-020-06114-x]

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb